


# Malaysia

Western Pacific Region



## I. Epidemiological profile


Population (UN)	2015	%	Parasites and vectors
Number of active foci	-		Plasmodium species: <i>P. falciparum</i> (7%), <i>P. vivax</i> (4%)
Number of people living within active foci	1,531,007	5	Major anopheles species: <i>An. balabacensis</i> , <i>An. donaldi</i> , <i>An. maculatus</i> , <i>An. sundaicus</i> , <i>An. flavirostris</i>
Malaria-free (0 cases)	28,800,000	95	Reported confirmed cases (health facility): 1,875 Estimated cases: 2,000 [1,900 ; 2,300]
Total	30,331,000		Confirmed cases at community level: - Reported deaths: 8 Estimated deaths: <10

## II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted						
ITN	ITNs/ LLINs distributed free of charge	Yes	1995	First-line treatment of unconfirmed malaria	-	-						
	ITNs/ LLINs distributed to all age groups	Yes	1995	First-line treatment of <i>P. falciparum</i>	AS+MQ	-						
IRS	IRS is recommended	-	-	Treatment failure of <i>P. falciparum</i>	QN+T	-						
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS+D; QN	-						
Larval control	Use of larval control recommended	Yes	1901	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	-						
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.50 mg/Kg (14 days)						
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-	Type pf RDT used		-						
	Malaria diagnosis is free of charge in the public sector	Yes	1967									
Treatment	ACT is free of charge for all ages in public sector	Yes	2008	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>								
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species	
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2013	CQ	2012-2014	61.9	61.9	61.9	28 days	1	<i>P. vivax</i>	
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	1993	CQ+PQ	2006-2007	4.3	4.3	4.3	28 days	1	<i>P. vivax</i>	
	G6PD test is a requirement before treatment with primaquine	Yes	1993	<b>Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)</b>								
	Directly observed treatment with primaquine is undertaken	Yes	-	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested			
System for monitoring adverse reactions to antimalarials exists	Yes	2003	2010-2014									
Surveillance	ACD for case investigation (reactive)	Yes	1965									
	ACD of febrile cases at community level (pro-active)	Yes	1965									
	Mass screening is undertaken	Yes	1965									
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	2013									
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	2013									
	Foci and case investigation undertaken	Yes	1995									
Case reporting from private sector is mandatory	Yes	1988										

## III. Financing

Sources of financing




Government expenditure by intervention in 2015




## IV. Coverage


Coverage of ITN and IRS




Cases tested



Cases treated




Cases tracked




## V. Impact

Confirmed malaria cases per 1000 and ABER



Number of malaria cases



**Notes:**  
Reported confirmed cases and reported deaths are indigenous only